In an interaction study based on data from 17 patients, assessing the effect of omeprazole, a potent CYP2C19 inhibitor, there was no significant effect on the pharmacokinetics of bortezomib.
Koostoime uuringus, mis põhines 17 patsiendi andmetel ja hindas tugevatoimelise CYP2C19 inhibiitori omeprasooli toimet, ei täheldatud olulist toimet bortesomiibi farmakokineetikale.